Lopinavir: Clinical Trials

31 trials of Lopinavir, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

24 completed, 3 recruiting, 2 terminated, 1 suspended. 31 Phase 1, 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 131Completed 24, Recruiting 3, Terminated 2, Suspended 1, Unknown 1
Phase 26Completed 3, Recruiting 2, Terminated 1

Follow Lopinavir: new trials by email Literature Review of Lopinavir trials Research Report on Lopinavir

Trials (filtered) newest first · largest first

All 31 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Lopinavir/Ritonavir in PLWH With High-Grade AIN
Lopinavir / Ritonavir - High-Grade Anal Intraepithelial Neoplasia
Phase 1RecruitingUniversity of Wisconsin, Madison212023-12-192026-05-15
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
DB-1311, Lopinavir and Ritonavir Tablets, itraconazole - Advanced Solid Tumors
Phase 1 / Phase 2RecruitingDualityBio Inc.8622023-08-172026-10-21
Bioequivalence Study of Lopinavir/Ritonavir 200/50 mg Film Tablet (World Medicine Ilac, Turkey) Under Fasting Conditions
Lopinavir/Ritonavir 200 mg/50 mg Film Tablet, Lopinavir/Ritonavir 200 mg/50 mg Film Coated Tablet - Bioequivalence
Phase 1CompletedWorld Medicine ILAC SAN. ve TIC. A.S.302020-04-302020-12-31
LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients
Lopinavir / Ritonavir, Remdesivir (RDV), Tocilizumab - COVID-19, Hospitalized COVID-19 Patients
Phase 1UnknownLebanese University10002020-03-282024-02-06
Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19
Wharton's jelly derived Mesenchymal stem cells., Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy) - Acute Respiratory Distress Syndrome
Phase 1 / Phase 2TerminatedBioXcellerator62020-01-132024-08-27
CiPA Phase 1 ECG Biomarker Validation Study
Ranolazine, Verapamil, Lopinavir / Ritonavir - Drug-induced QT Prolongation, Pharmacokinetics
Phase 1CompletedFood and Drug Administration (FDA)602017-03-142020-01-18
PK of Efavirenz & Lopinavir Nano-formulations in Healthy Volunteers
50mg NANO-efavirenz, 400mg NANO-Lopinavir, 200mg NANO-Lopinavir - HIV
Phase 1SuspendedSt Stephens Aids Trust502015-11-012016-12-07
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission
Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Nevirapine (NVP), Lopinavir/Ritonavir (LPV/r) - HIV Infection
Phase 1 / Phase 2RecruitingNational Institute of Allergy and Infectious Diseases (NIAID)11202015-01-232026-09-09
Changes in Insulin Resistance in Healthy Volunteers on STRIBILDĀ® Medication
Tenofovir disaproxil fumarate/emtricitabine/elvitegravir/cobicistat, Tenofovir disaproxil fumarate/emtricitabine + Lopinavir/ritonavir, Tenofovir disaproxil fumarate/emtricitabine + ritonavir-boosted darunavir - Insulin Resistance
Phase 1CompletedTechnical University of Munich302014-07-012014-11-05
Study Assessing the Effects of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy Participants
Daclatasvir, Darunavir, Ritonavir - Hepatitis C
Phase 1CompletedBristol-Myers Squibb492014-06-012015-11-30
Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected
Lopinavir/ritonavir, Emtricitabine/tenofovir disoproxil fumarate, Efavirenz - HIV-1 Infection, Pf Subclinical Parasitemia
Phase 1 / Phase 2CompletedAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections522014-01-102019-08-06
Drug-drug Interaction Study Between Lopinavir/Ritonavir and Isavuconazole
Isavuconazole, Lopinavir/ritonavir - Pharmacokinetics of Isavuconazole, Pharmacokinetics of Lopinavir/Ritonavir
Phase 1CompletedAstellas Pharma Global Development, Inc.682012-06-012015-02-23
Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin
PA-824, Efavirenz (EFV), Lopinavir/Ritonavir (LPV/r) - Tuberculosis
Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)522012-05-012021-11-05
The Influence of Ritonavir, Alone and in Combination With Lopinavir, on Fenofibric Acid Pharmacokinetics in Healthy Volunteers
Fenofibrate, Ritonavir, Lopinavir/Ritonavir - HIV, Fenofibrate
Phase 1CompletedNational Institutes of Health Clinical Center (CC)252010-05-132019-12-09
Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir/Ritonavir)
Kaletra (lopinavir/ritonavir), African Potato (hypoxis obtusa) - Drug Interactions, Human Immunodeficiency Virus
Phase 1CompletedUniversity of California, San Francisco182010-02-012015-05-07
Pharmacokinetics of Lopinavir/Ritonavir at Three Different Doses.
lopinavir/ritonavir - Acquired Immunodeficiency Syndrome
Phase 1CompletedKirby Institute222009-10-012011-03-29
Drug Interaction Study of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK2248761 PK and CYP450 Probe Drugs
darunavir/ritonavir, lopinavir/ritonavir, Midazolam - Healthy Subjects, Infection, Human Immunodeficiency Virus
Phase 1CompletedGlaxoSmithKline242009-06-012010-11-03
GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/Ritonavir
Darunavir, Etravirine, Ritonavir - Healthy Volunteer
Phase 1CompletedViiV Healthcare172009-04-012012-02-22
Drug Interaction Study Between Eltrombopag and Lopinavir/Ritonavir in Healthy Adult Subjects.
Eltrombopag, Lopinavir/Ritonavir, Eltrombopag and Lopinavir/Ritonavir - Hepatitis C
Phase 1CompletedGlaxoSmithKline402009-01-192017-11-14
TMC125-TiDP2-C197: A Phase I Trial to Investigate the Pharmacokinetic Interaction Between Lopinavir/Ritonavir and TMC125 Both at Steady-state in Healthy Volunteers.
Etravirine; Lopinavir; Ritonavir - HIV
Phase 1CompletedTibotec Pharmaceuticals, Ireland162008-09-012011-06-09

Showing 20 of 31. Sign in to see all of them.

Conditions studied

HIV Infections (11)  ·  Acquired Immunodeficiency Syndrome (4)  ·  Hepatitis C (2)  ·  Malaria (2)  ·  Tuberculosis (2)  ·  COVID-19 (1)  ·  Carcinoma, Hepatocellular (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Coronavirus Infections (1)  ·  Disease Progression (1)  ·  Esophageal Squamous Cell Carcinoma (1)  ·  Hypertriglyceridemia (1)  ·  Infections (1)  ·  Inflammation (1)  ·  Insulin Resistance (1)

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID) (4)  ·  Abbott (3)  ·  GlaxoSmithKline (2)  ·  St Stephens Aids Trust (2)  ·  University of California, San Francisco (2)  ·  Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (1)  ·  Astellas Pharma Global Development, Inc. (1)  ·  BioXcellerator (1)  ·  Bristol-Myers Squibb (1)  ·  DualityBio Inc. (1)  ·  Food and Drug Administration (FDA) (1)  ·  Fran Aweeka (1)  ·  Germans Trias i Pujol Hospital (1)  ·  Kirby Institute (1)  ·  Lebanese University (1)

Countries

United States (20)  ·  Puerto Rico (3)  ·  United Kingdom (3)  ·  Brazil (2)  ·  Kenya (2)  ·  Malawi (2)  ·  Uganda (2)  ·  Argentina (1)  ·  Australia (1)  ·  China (1)  ·  Colombia (1)  ·  Germany (1)  ·  Haiti (1)  ·  Lebanon (1)  ·  Netherlands (1)

Top investigators

Alfredo Hernandez-Ruiz, MSc (1)  ·  Angela DM Kashuba, PharmD (1)  ·  Angela Nilius, MD (1)  ·  Bonaventura Clotet, MD, PhD (1)  ·  Carlos Sanabria, MD (1)  ·  Christoph D Spinner, MD (1)  ·  David M Burger (1)  ·  Douglas Shaffer, MD, MHS (1)  ·  Ellen Chadwick, MD (1)  ·  Ellen G. Chadwick, MD (1)  ·  Evie Carchman, MD, FACS (1)  ·  Francesca Aweeka, Pharm.D. (1)  ·  Francesca T Aweeka, Pharm.D. (1)

Results publications

PMID 17436219, PMID 18625762, PMID 18647794, PMID 19209098, PMID 20056686, PMID 21172791, PMID 21297419, PMID 22288567, PMID 22555165, PMID 23494984, PMID 24957823, PMID 30447156, PMID 34693933

NIH funding

2004 (1), 2014 (1), U01AI068636 (1), UM1AI068616 (1), UM1AI068632 (1), UM1AI106716 (1)